<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00532168</url>
  </required_header>
  <id_info>
    <org_study_id>ADVANZ-3</org_study_id>
    <secondary_id>EudraCT: 2006-006268-42</secondary_id>
    <secondary_id>FIS grant: EC07/90642</secondary_id>
    <nct_id>NCT00532168</nct_id>
  </id_info>
  <brief_title>Once-daily Antiretroviral Therapy in HIV-1 Infected Patients With CD4+ Cell Counts Below 100 Cells/Mcl</brief_title>
  <acronym>ADVANZ-3</acronym>
  <official_title>Once-daily Antiretroviral Therapy in HIV-1 Infected Patients With CD4+ Cell Counts Below 100 Cells/Mcl. A Prospective, Randomized, Multicentre, Open Clinical Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Juan A. Arnaiz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Clinic of Barcelona</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      There are few randomized clinical trials in advanced HIV patients. This is a multicenter,
      randomized, open clinical trial, comparing three parallel groups, to compare the
      immunological reconstitution and the virological efficacy and safety of three different
      combinations of antiretroviral therapy given once a day (QD): tenofovir plus emtricitabine
      plus either efavirenz, lopinavir-ritonavir or atazanavir-ritonavir during 96 weeks in
      advanced antiretroviral naïve HIV-1 infected patients with less than 100 CD4+ T-cells/mm3.
      Primary endpoint is the median increase in CD4+ T-cell count at 48 weeks after starting
      HAART.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2007</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Median increase in CD4+ T-cell count at 48 weeks after starting the HAART combination randomly assigned</measure>
    <time_frame>48 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">108</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>tenofovir plus emtricitabine plus efavirenz</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>tenofovir plus emtricitabine plus lopinavir-ritonavir</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>tenofovir plus emtricitabine plus atazanavir-ritonavir</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tenofovir + emtricitabine + efavirenz</intervention_name>
    <description>tenofovir + emtricitabine + efavirenz, approved dose, oral route, QD</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tenofovir + emtricitabine + lopinavir-ritonavir</intervention_name>
    <description>tenofovir + emtricitabine (QD) + lopinavir-ritonavir (BID), oral route, approved dose</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tenofovir + emtricitabine + atazanavir-ritonavir</intervention_name>
    <description>tenofovir + emtricitabine + atazanavir + ritonavir (100 mg), oral route, approved dose, QD</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Chronic HIV-1 infection

          -  Age 18 or more

          -  Antiretroviral-naive

          -  Baseline CD4+ count &lt;100 cels/mcL.

          -  No mutations of drug resistance at baseline (M184V/I, K65R, resistance to efavirenz or
             2 or more PRAMs (L33I/F/V, V82A/F/L/T, I84V, L90M)

          -  Written informed consent

        Exclusion Criteria:

          -  Hypersensibility to study drugs.

          -  Pregnancy or breastfeeding

          -  Active OI requiring admission

          -  Active lymphoma or malignancy (Kaposi sarcoma included)

          -  Cl creatinine below 30 ml/min.

          -  Liver failure

          -  Treatment with nephrotoxic drugs, immunomodulators, interleukine-2, systemic steroids
             or investigational products.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jose M Miró, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital Clinic of Barcelona</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Clinic</name>
      <address>
        <city>Barcelona</city>
        <state>Catalonia</state>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>February 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 18, 2007</study_first_submitted>
  <study_first_submitted_qc>September 19, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 20, 2007</study_first_posted>
  <last_update_submitted>February 21, 2013</last_update_submitted>
  <last_update_submitted_qc>February 21, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 22, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Clinic of Barcelona</investigator_affiliation>
    <investigator_full_name>Juan A. Arnaiz</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>advanced HIV-infected patients</keyword>
  <keyword>late presenters</keyword>
  <keyword>antiretroviral therapy</keyword>
  <keyword>immune reconstitution</keyword>
  <keyword>Treatment Naive</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Lopinavir</mesh_term>
    <mesh_term>Atazanavir Sulfate</mesh_term>
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Emtricitabine</mesh_term>
    <mesh_term>Efavirenz</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

